Skip to main content
Premium Trial:

Request an Annual Quote

Sensyne Health, Colorado Center for Personalized Medicine Sign Data Deal for Research

NEW YORK – Sensyne Health said Monday that it has entered into a research partnership with the Colorado Center for Personalized Medicine to enable the "ethical application" of clinical artificial intelligence to support both research and patient care.

This represents the Oxford, UK-based startup's second research agreement in the US. The first, with St. Luke's University Health Network in Pennsylvania and New Jersey, was announced last week.

CCPM, a partnership between the University of Colorado Anschutz Medical Campus and the UCHealth provider network, will provide deidentified data from its dataset of 7.3 million patients, including its biobank covering more than 180,000 individuals. CCPM has experience returning clinically actionable genomic results through its research biobank and integrating personalized genomic information with clinical data.

Sensyne, a developer of AI technology for remote patient monitoring and real-time clinical decision-making, will mine this data to help pharmaceutical clients accelerate the development of new drug compounds.

According to the agreement, CCPM will share an unspecified portion of revenues generated from any research on CCPM data that Sensyne and its partners are able to commercialize.

"Our partnership with Sensyne Health will lead to an optimization of patient care, using personalized results to better inform research, clinical decision-making, and potentially leading to new ways of diagnosing, preventing, and treating illnesses," CCPM Director Kathleen Barnes said in a statement.

"This agreement with Colorado Center for Personalized Medicine, covering both genomic and electronic health record data, will enable us to undertake research aimed at a deeper understanding of disease, and to accelerate the development of novel medicines in collaboration with our pharmaceutical partners," added Sensyne Health CEO Paul Drayson.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.